-- Knight Therapeutics (GUD.TO) 周四表示，公司第一季度净利润和调整后营收均大幅增长，超出预期，并上调了2026年营收预期。 净利润飙升503%，达到1320万美元，合每股0.13美元，而去年同期为220万美元，合每股0.02美元。根据FactSet的数据，这一业绩超过了市场普遍预期的每股0.03美元。 剔除大部分一次性项目后，调整后营收增长68%，达到1.476亿美元，高于此前预期的1.1406亿美元。该公司表示，营收增长主要得益于Paladin和Sumitomo产品组合带来的增量收入、公司主推产品的增长，以及包括向巴西卫生部交付Ambisome在内的部分产品的采购模式。 Knight Therapeutics公司将2026财年营收预期从4.9亿美元至5.1亿美元上调至5.1亿美元至5.25亿美元。调整后EBITDA预计占营收的15%。营收预期上调主要得益于其推广产品在包括加拿大、墨西哥和哥伦比亚在内的多个国家/地区的良好表现，以及拉丁美洲货币兑加元汇率的预期改善。 周三，Knight Therapeutics的股票在多伦多证券交易所收盘下跌0.04美元，报7.51美元。
Related Articles
Australia
Vericel Shares Rise After Q1 Net Loss Narrows, Revenue Rises; 2026 Revenue Guidance Lifted
Vericel (VCEL) shares were up 1.3% in Thursday trading after the company posted a narrower net loss and higher revenue for Q1, and raised its full-year revenue guidance.The company reported Thursday Q1 net loss of $0.12 per diluted share, narrowing from a loss of $0.23 a year earlier.Analysts polled by FactSet expected a loss of $0.15.Revenue for the quarter ended March 31 was $68.4 million, up from $52.6 million a year earlier.Analysts surveyed by FactSet expected $63.7 million.The company said it now expects 2026 total revenue to be between $326 million and $336 million, compared with previous guidance of $316 million to $326 million. Analysts polled by FactSet expect $323.4 million.Price: $37.26, Change: $+0.48, Percent Change: +1.31%
$VCEL
Australia
Liquidity Services Fiscal Q2 Adjusted Earnings, Revenue Increase; Shares Fall
Liquidity Services (LQDT) shares were down nearly 2% in Thursday early trading even after the company reported fiscal Q2 adjusted earnings and revenue that increased year on year and beat analysts' estimates.The company reported fiscal Q2 adjusted earnings of $0.35 per diluted share, up from $0.31 a year earlier.Two analysts polled by FactSet expected $0.30.Revenue for the quarter ended March 31 was $120.7 million, up from $116.4 million a year earlier.One analyst surveyed by FactSet expected $52.9 million.The company expects fiscal Q3 adjusted EPS of $0.30 to $0.39. Two analysts polled by FactSet expect $0.37.Price: $35.83, Change: $-1.39, Percent Change: -3.73%
$LQDT
Research
Research Alert: Grainger Q1 Earnings Jump As Margin Recovery Takes Hold
CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:GWW delivered strong Q1 results with EPS of $11.65, up 18.2% Y/Y, significantly beating consensus expectations of $10.21. Sales reached $4.7B with 12.2% organic growth, supported by robust underlying demand across both business segments. The standout metric was 110-bp operating margin expansion to 16.7%, which we view as an inflection point from margin pressures that were a factor for much of 2025, driven by aggressive pricing actions to offset tariff-related cost inflation. Management raised full-year 2026 EPS guidance to $44.25-$46.25 from the previous $42.25-$44.75 range following the uptick in business conditions. Margin recovery was broad-based with High-Touch Solutions North America expanding 20 bps to 42.6% and Endless Assortment growing 40 bps while achieving strong 21.9% sales growth from MonotaRO and Zoro performance. Strong cash generation of $739M supported $345M in shareholder returns and a 10% dividend increase.
$GWW